GlassScriptPhysician profile
James Matthew Mobley
NPI 1184018285
$3,178.62
in general payments reported to CMS, 2019-2025
39 companies · $1,171 in 2025
The $1,171 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $240 · 2023: $369 · 2024: $1,399 · 2025: $1,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,938.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $427.88 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $384.85 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $279.79 | 2022-2025 | Opdivo |
| Janssen Biotech, INC. | $150.36 | 2024-2025 | Darzalex, Talvey, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $134.58 | 2023-2025 | Lynparza, Enhertu, Imfinzi |
| Pfizer INC. | $130.16 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $129.05 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $99.53 | 2022 | |
| Daiichi Sankyo INC. | $91.94 | 2024-2025 | Enhertu, Vanflyta |
| Incyte Corporation | $91.28 | 2024-2025 | Jakafi, Monjuvi |
| Astellas Pharma US INC | $87.41 | 2024-2025 | Xospata, Padcev |
| Regeneron Healthcare Solutions, INC. | $85.46 | 2024-2025 | Libtayo, Lynozyfic |
| Gilead Sciences, INC. | $84.89 | 2025 | Trodelvy |
| Emd Serono, INC. | $82.02 | 2023-2024 | Bavencio |
| Array Biopharma INC | $77.33 | 2025 | Braftovi, Mektovi, Tukysa |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $58.00 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.28 | 2024-2025 | Alunbrig, Fruzaqla, Iclusig |
| Mirati Therapeutics, INC. | $56.42 | 2023-2024 | Krazati |
| Bayer Healthcare Pharmaceuticals INC. | $54.86 | 2024-2025 | |
| Genzyme Corporation | $54.55 | 2024-2025 | |
| Adaptive Biotechnologies Corporation | $46.70 | 2024 | Clonoseq |
| Genentech USA, INC. | $43.78 | 2023-2025 | Itovebi, Phesgo |
| Exelixis INC. | $40.95 | 2022-2024 | Cabometyx |
| Kite Pharma, INC. | $40.30 | 2024 | Yescarta |
| Celgene Corporation | $38.88 | 2023 | Opdualag, Pomalyst |
| Karyopharm Therapeutics INC. | $38.67 | 2024 | Xpovio |
| Glaxosmithkline, LLC. | $35.25 | 2024-2025 | Ojjaara |
| Pharmaessentia USA Corporation | $33.88 | 2024 | Besremi |
| Beigene USA, INC. | $31.83 | 2024 | Brukinsa |
| Stemline Therapeutics INC. | $24.77 | 2024 | Orserdu |
| Geron Corporation | $24.30 | 2025 | Rytelo |
| Cti Biopharma Corp. | $23.63 | 2023 | Vonjo |
| Eisai INC. | $22.00 | 2024 | |
| Genmab U.S., INC. | $21.84 | 2024 | Epkinly |
| Springworks Therapeutics, INC. | $21.79 | 2025 | Ogsiveo |
| Morphosys, US INC. | $21.60 | 2023 | Monjuvi |
| Blueprint Medicines Corporation | $19.27 | 2022 | |
| Legend Biotech USA INC. | $15.90 | 2024 | |
| Sobi, INC | $15.64 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mobley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.